Contact No: +91-8826373757 | +91-8826859373 | 011-25052216
Email: rakesh.its@gmail.com | editor@innovativepublication.com

Indian Journal of Pathology and Oncology


Role of glial fibrillary acidic protein (GFAP) marker in central nervous system lesions


Full Text PDF Share on Facebook Share on Twitter


Author Details: Geeta W. Mukhiya, Gulshan K. Mukhiya, KK Bansal

Volume : 4

Issue : 3

Online ISSN : 2394-6792

Print ISSN : 2394-6784

Article First Page : 465

Article End Page : 467


Abstract

Introduction: The subject of tumours of the nervous system is often looked upon with apprehension by medical practitioners as central nervous system tumours constitute 1-2% of all the neoplasms. Gliomas constitute 38.7% of CNS tumours in which high grade gliomas are 59.5% of patients with systemic malignancies develop brain metastasis during their disease.
Glial fibrillary protein is the most frequently used marker in diagnostic neuro-oncology. Positive reaction to GFAP has been demonstrated in astrocytomas, ependymoma and astrocytic cells of mixed gliomas, subependymal giant cell astrocytoma, pleomorphic xanthoastrocytoma, astroblastoma and gliosarcoma.
Aim of the study: In the present study the main aim is to differentiate glial tumours from other lesions by morphology and confirmation by using Glial Fibrillary Acidic Protein (GFAP) immunostaining.
Results: In the present study glial tumors formed the largest group of cases (44 cases; 41.9%) diagnosed on cytology. They were further divided into low grade and high grade glioma / astrocytoma (33 cases, 31.4%), oligodendroglioma (1 case, 0.95%) and ependymoma (7 cases, 6.6%) based on cytological features. Subsequently, as shown in table IX, the cytohistopathological correlation for glioma / astrocytoma was 91.6%. There were 10 cases which turned out to be oligodendroglioma (4 cases, 11.1%), ependymoma (4 cases, 11.1%) and ganglioglioma (2 cases, 6.0%).

Keywords:
GFAP, Glial Fibrillary Protein, Astrocytomas, Ependymoma